

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 136 077 A1**

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
26.09.2001 Bulletin 2001/39

(51) Int Cl.7: **A61K 39/29, A61K 39/295**

(21) Application number: **99957844.6**

(86) International application number:
PCT/CU99/00006

(22) Date of filing: **01.12.1999**

(87) International publication number:
WO 00/32229 (08.06.2000 Gazette 2000/23)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **02.12.1998 CU 18398**

(71) Applicant: **CENTRO DE INGENIERIA GENETICA Y
BIOTECNOLOGIA (CIGB)**
Ciudad de la Habana 10600 (CU)

(72) Inventors:
• **AGUILAR, Rubido Julio César**
Guanajay, Ciudad de la Habana 32200 (CU)
• **PALENZUELA GARD N. Daniel Octavio**
Artemisa, Ciudad de la Habana 33800 (CU)

- **MUZIO GONZ LEZ, Verena Lucila**
Nuevo Vedado, Ciudad de la Habana 10600 (CU)
- **GUILL N NIETO, Gerardo Enrique**
Vedado, Ciudad de la Habana 10400 (CU)
- **PENTON ARIAS, Eduardo, Apartamento 49**
Playa, Ciudad de la Habana 12100 (CU)
- **PICHARDO DIAZ, Dagmara Apartamento 32**
La Lisa Ciudad de la Habana 13600 (CU)
- **IGLESIAS PEREZ, Enrique Edificio 25**
Apartamento103
de la Habana 11700 (CU)

(74) Representative: **Prins, Adrianus Willem et al**
Vereenigde,
Nieuwe Parklaan 97
2587 BN Den Haag (NL)

(54) **PREPARATIONS CONTAINING VIRUS-LIKE PARTICLES AS IMMUNOPOTENTIATORS
ADMINISTERED THROUGH THE MUCOSA**

(57) The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens.

The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation.

These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen.

Stabilizers and preservatives can be introduced.

The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.

EP 1 136 077 A1

Description

Technical branch

[0001] The present invention is related to the branch of medicine, particularly with the use of new vaccine immunoenhancing strategies. In this case, the adjuvant is a virus-like particle (VLP), which at the same time constitutes an antigen of interest in the formulation. The adjuvant mechanism is based on the positive effect of one antigen on others or on the synergic interaction between the antigens of the formulation.

Previous technique

[0002] The technical objective pursued with the present invention is, precisely, the development of formulations capable of enhancing the immune response to antigens administered through mucosal routes, minimizing the number of components in the formulation. The enhancing activity is supported by the interaction between particles at the mucosal level, generating systemic as well as mucosal immunity. Furthermore, the development of combined vaccines to the mucosal route taking as a central antigen the HBsAg, increased the immune response to one or more of coadministered antigens. The obvious advantage is the elimination of all other element or compounds different from the antigen of interest and the use of a different route. We consider that this is the basis or nucleus to develop combined vaccines for a mucosal use.

[0003] HBcAg is an extremely immunogenic antigen during the Hepatitis B Virus (HBV) infection or after immunization. In many HBV chronic patients, this is the only antigen capable of inducing an immune response. It can even induce an immune response in mice in nanogram quantities. Recently, a few structural studies have demonstrated some important characteristics explaining its potent immunogenicity. HBcAg specifically binds membrane immunoglobulin receptors in a large number of resting B cells in mice, which is sufficient to induce costimulatory B7-1 and B7-2 molecules. In this way, non-sensitized B cells, specific for HBcAg can uptake, process and present HBcAg peptides to naive T cells *in vivo* and to T cells hybridoma *in vitro*, approximately 10^5 times more efficiently than macrophages and dendritic cells. This structure-function relationship explains the great immunogenicity of HBcAg (Milich, D.R. *et al.* 1997 Proc. Natl. Acad. Sci USA Dec23; 94(26): 14648-53).

[0004] Serologic and biochemical studies indicate that the resolution of HBV acute infection occurs in the context of an efficient cell-mediated immune response, while the chronic infection is characterized by a poor and undetectable cell-mediated immune response and a "relatively efficient" humoral response.

[0005] The humoral immunity and the cell-mediated immunity are regulated by different groups of helper T

cells. Factors influencing the induction in mice of a Th1 or Th2 response to the HBV antigens (HBcAg/HBeAg) revealed that this balance was influenced (1) by the antigen structure (HBcAg is a particulated structure and HBeAg is not; (2) the major histocompatibility complex (MHC) of the host and the T cell antigens which are recognized; (3) the cross regulation between Th 1 and Th2 cells; (4) the T cell tolerance, which is more complete for Th1 than for Th2 cells; (5) the activity of secreted HBeAg that preferentially delete Th1 cells (6) the treatment with cytokines, used to modulate *in vivo* the response toward Th1 or Th2 cells. This balance Th1/Th2 is relevant to the acute or chronic course of the HBV infection. Th2 cells preferentially evade the induction of tolerance compared with Th1. As HBeAg acts as a tolerogen during HBV vertical transmission, deleting Th1 cells, the predominance of Th2 specific cells for HBeAg could influence in the initiation and maintenance of a chronic carrier state. In this case the cytokine therapy endowed to modulate the response towards Th1, could be beneficial in the treatment of HBV chronic infection (Milich, D.R. 1997 J. Viral. Hepat.; 4 Suppl 2: 48-59).

[0006] The effect of HBeAg circulation on HBcAg Th1 specific T cells was examined by transferring HBeAg/HBcAg specific T cells to double (HBeAg and HBcAg) transgenic mice. The presence of serum HBeAg eliminated the Th1 mediated response against HBcAg and changed the balance to the Th2 phenotype. This result suggest that, in the context of the hepatitis B infection, circulating HBeAg has the potential to preferentially eliminate inflammatory specific Th1 cells needed for viral clearance, promoting the persistency of HBV (Milich-DR *et al.* 1998 J-Immunol. Feb 15; 160(4): 2013-21).

[0007] It is known that antibodies against HBcAg are present since the beginning of the infection and reach high concentrations in sera of HBV chronically infected patients, but these antibodies are not protective. Antibodies passively transmitted to newborn children by chronic carrier mothers, do not protect children of infection. (Beasley *et al.* 1977. American Journal of Epidemiology 105: 914-918). However, it has been demonstrated that immunizing chimps with HBcAg partially or completely protected them from HBV infection (Iwarson, S. *et al.* 1985 Gastroenterology 88: 763-767; Murray, K. *et al.* 1987 Journal of Medical Virology 23: 101-107). In Iwarson's study, three chimps were completely protected. After challenge with HBV, antibody levels against HBcAg and HBeAg increased but only one chimp seroconverted against HBsAg. In Murray's study, 2 out of 4 immunized chimps showed a low level of viral replication after challenge, HBsAg was detectable in sera for 2 or 3 weeks, and after that they developed an anti-HBsAg antibody response. It was hypothesized that the incomplete protection could be due to the low immune response in vaccinated animals without adjuvant.

[0008] After immunizing with woodchucks hepatitis core antigen (WHcAg) in Freund Complete Adjuvant

(ACF), it was possible to protect woodchucks from challenge with the virus (WHV) without signs of infection detectable antibodies against the surface protein (WHsAg). Although the hypothesis that T helper anti-nucleocapsid immune response could enhance undetectable antibodies against the surface antigen can not be discarded, the cytotoxic activity was considered as the main responsible of protection (Roos, S. *et al.* 1989 J. Gen. Virol. 70, 2087-2095). In a second study using woodchucks the role of HBcAg and WHcAg in protection was determined as well as the possible mechanism. Animals were immunized with WHcAg and HBcAg and afterwards challenged using a high dose of WHV. In this experiment it was found that WHcAg is a protecting antigen there is a cross protection because 4 out of 6 woodchucks immunized with HBcAg were protected from the challenge. Both antigens generated a high antibody titer with a cross reactivity lower than 1%, confirming previous reports of protection using internal hepatitis B virus antigens. Since dominant B epitopes of both antigens do not appear to be conserved, this result also demonstrated that antibodies directed against core antigens are not important for protection. Woodchucks immunized with WHcAg/HBcAg reacted with a rapid response of serum antibodies against surface proteins after challenge with WHV, indicating an increased helper T cell response as a potential mechanism of protection after immunization with an internal antigen of HBV/WHV. (Schodel-F *et al.* Vaccine. 1993; 11(6): 624-8)

[0009] Transfection of established cell lines from BALB/C mice hepatocytes with dimeric HBV DNA (ML lines) resulted in the expression of HBV antigens in these lines. The adoptive transference of spleen cells of BALB/c mice immunized with ML-1.1 cells expressing HBsAg as well as HBcAg, caused a regression of tumours cells expressing the corresponding antigens in athymic mice. Furthermore, the transfer of spleen cells of BALB/c mice immunized with HBsAg or HBcAg also caused tumoral regression. These results demonstrated that surface and nucleocapsid antigens could induce immunity capable of rejecting the hepatocellular carcinoma *in vivo* (Chen, S.H. *et al.* 1993 Cancer-Res. Oct 1; 53(19): 4648-51).

[0010] Therapeutic vaccines based on specific nucleocapsid epitopes for human HLA are being assayed in phase II/III studies (Liaw, Y.F. 1997 J.Gastroenterol. Hepatol. Oct, 12 (9-10): S227-35).

[0011] HBcAg has been demonstrated to be a very good carrier. HBcAg represents a highly immunogenic antigen in human and animal models. HBcAg activates directly B cells and generates strong T cell responses, furthermore, the efficient processing and presentation of HBcAg by the antigen presenting cells makes it the ideal carrier molecule. Hence a large number of epitopes has been chemically linked or genetically fused to the HBcAg molecule to successfully increase their immunogenicity. Expression vectors has been designed in bacteria to enable the insertion of heterologous B cell

epitopes in different positions inside the particles of HBcAg and the efficient purification of hybrid particles.

[0012] Positional studies of B cell epitopes demonstrated that internal insertions by the amino acid 80 continue to be immunodominant, permitting an increase in the production of antibodies as compared to other fusion proteins.

[0013] Immunogenicity studies have been performed with experimental challenge in different systems. For example, a peptide from *Plasmodium berghei* Circumsporozoite was inserted in this site and the purified hybrid particle HBcAg/CS was highly immunogenic and protected 100% of challenged mice against malaria. Aimed to the development of oral vaccines, attenuated avirulent Salmonella strains have been used to introduce genes coding for hybrid particles of HBcAg (Milich, D.R. *et al.* 1995 Ann. N.Y. Acad. Sci. May 31; 754: 187-201).

[0014] In conclusion, apart from the relationship between HBcAg and protection, total or partially evidenced in chimps or indirectly referred by the experiments with WHcAg, this protein has a number of properties that makes it unique. HBcAg behaves as a T dependent as well as a T independent antigen (Milich, D.R. *et al.* 1986 Science 234, 1398-1401), it is very immunogenic, even without the help of adjuvants and its inoculation preferentially sensitises Th1 cells (Milich, D.R. *et al.* 1997, J. Virol. 71, 2192-2201). HBcAg is a very efficient carrier protein (Schodel, F. *et al.* 1992 J. Virol. 66: 106-114; Milich-DR *et al.* 1995 Ann-N-Y-Acad-Sci. May 31; 754: 187-20) and Th HBcAg specific cells mediate the antibody response against HBcAg as well as anti-HBsAg (Milich, D.R. *et al.* 1987 Nature (London) 329: 547-549). These immunologic characteristics are unique for the particulated HBcAg and do not apply to the non-particulated form of the antigen, the HBeAg (Milich, D.R. *et al.* 1997 Proc. Natl. Acad. Sci USA Dec 23; 94(26): 14648-53).

Detailed description of the invention

[0015] In the present invention it is reported for the first time a vaccine formulation having as main compounds: HBsAg and HBcAg in adequate proportions. Other compounds may be introduced as stabilizers and preservatives.

[0016] The novelty of HBsAg/HBcAg formulation is linked to the anti HBsAg enhancing effect generated when HBsAg is mixed with HBcAg. Both antigens are compounds of HBV and hence, the role of the adjuvant is taken by other viral antigen attractive *per se* as a vaccine antigen, becoming a vaccine formulation with a wider anti-hepatitis B immune response spectrum. Other formulations of nucleocapsid antigens combined with surface antigens, for example the formulation HBsAg/Virus like particle of Human Papilloma Virus and extended to other viral antigens, results in an increase in titers against both antigens. After mixing HBsAg with other

antigens, an increase in the immunogenicity over other coinoculated antigens could be shown, evidencing a synergic effect produced by the combination X + HBsAg through the nasal route. In general, these results enables the generation of HBsAg mucosal combined vaccines, and enables the use of the positive interactions between VLP, considering VLP as organized proteic or lipoproteic structures, resembling viruses, with a size of nanometers.

[0017] In the case of the formulation containing HBsAg and HBcAg, we can obtain a superior product as compared to the single HBsAg commercially available vaccine because:

- It is possible to obtain a wider spectrum of immune response generated by HBcAg regarded as an important antigen *per se* in anti-VHB protection. Furthermore, the IgG seric levels anti-HBsAg reached by mucosal inoculation is as intense as the one obtained with the systemic inoculation in alum.
- The route of inoculation offers special advantages such as: systemic and mucosal immunity at the same time, the elimination of strong quality controls such as sterility and pyrogens as well as the high prices of injected vaccines, the related toxicity.
- The toxic effect generated by alum-based vaccines and the toxic effects of adjuvant injection can be avoided because the antigen number 2 is at the same time the adjuvant.
- It is possible to use the initial HBsAg + HBcAg formulation as a nucleus of combined vaccines.
- It is possible to immunize non-responders to the surface antigen and immunodepressed patients using this preparation, due to the inoculation route and the introduction of the nucleocapsid antigen regarded as a protective antigen *per se*.
- The characteristics of this formulation make it an ideal formulation for therapeutic use.

[0018] In the second place, nucleocapsid antigens, favour the increase of coinoculated antigens immunogenicity. We found a great simplicity of resulting formulations and, at the same time, the increased valence of these potential vaccines with a minimal number of antigens due to the possibility of avoiding the use of adjuvants, which are *per se* non-interesting antigens for protection. In this way very reduced combinations can be obtained if desired, for single or combined vaccines.

[0019] In the third place, it is possible to generate combined vaccines having as a nucleus the HBsAg whose immunoenhancing effect on other coinoculated antigens is demonstrated in the example 4. The advantages of these formulations are based on the effective association of HBsAg, as a central antigen of the anti HBV vaccine, with other antigens, with a demonstrated synergic effect in the generated response for both antigens. This fact, not only has the attraction of previously described variants but it also makes the HBsAg, -pro-

tecting antigen for a widely distributed world disease-the central antigen of combined formulations.

[0020] In general terms, compared to other mucosal vaccines, it is possible to detach the following advantages:

- The 'adjuvation' process -mixing antigens- does not require the adsorption of antigens, and the quantity of the HBcAg antigen is at similar levels of HBsAg.
- The filtration as a sterilizing process can be used due to the small size of the particles, while other strategies and adjuvants over 0.2µm can not be sterilized in this way.
- The simplicity of the production process for HBcAg makes it a very cheap antigen as compared to other adjuvants.

[0021] The formulations object of the present invention may present volumes from 0.01 until 10mL, depending of the inoculation route and the species to immunize. The antigen doses vary in a range of 0.001 to 1mg.

EXAMPLES OF PERFORMANCE

Example 1

[0022] With the aim of evaluating the immunogenicity of HBcAg through the nasal route, 3 groups of 8 female BALB/c mice were inoculated with a dose of 10µg of HBcAg in all cases. The first group was inoculated with HBcAg in acemannan (CIGB, La Habana) 3 mg/mL (dry weight), adjuvant previously used to increase the immunogenicity of particulated systems through the nasal route. The second group was inoculated with HBcAg in phosphatesaline (PBS) buffer. Group 3 was injected subcutaneously with the antigen in alum and used as a control group for systemic inoculation. The schedule was followed of inoculations on days 0, 14, 28 and the extraction was done on day 42. The antibody response was quantified by immunoenzymatic assay (ELISA) to determine the IgG antibodies against HBcAg in sera.

[0023] The Student's t test was performed to analyse statistically the results, $p < 0.05$ was considered a significant difference.

[0024] It was demonstrated that, with the use of acemannan it was impossible to increase the anti-HBcAg antibody immune response. The antigen in PBS generated an immune response of a similar intensity to that obtained using acemannan (Fig. 1). The responses after nasal inoculation, in acemannan or in PBS, were similar to the response obtained using alum systemically. In conclusion, HBcAg can be used through the nasal route with a high immunogenicity.

Example 2

[0025] With the aim of demonstrating the immunoenhancing activity of HBcAg on HBsAg when both are

mixed and inoculated through the nasal route, 4 groups of 8 female BALB/c mice were assayed. A two inoculations schedule was carried out. The inoculations were on days 0 and 14. The extraction was on day 21. The group 1. was inoculated with 10 μ g of HBsAg in PBS, group 2 with 10 μ g of HBsAg in acemannan (CIGB, La Habana) 3mg/mL (dry weight), group 3 with 10 μ g of HBsAg and 10 μ g of HBcAg. Group 4 was used as a systemic control, inoculating subcutaneously 10 μ g of HBsAg in alum (Fig. 2). The Student t test was performed to analyse statistically the results, $p < 0.05$ was considered a significant difference.

[0026] From this experiment we concluded that it is possible to enhance the anti HBsAg immune response with the inoculation through the nasal route of HBsAg and HBcAg. The anti HBsAg response was significantly superior as compared to the group when the HBsAg was inoculated in PBS and similar to that reached by the group inoculated in acemannan. The systemic inoculation of HBsAg in alum did not differ significantly from the groups inoculated with acemannan through the nasal route.

Example 3

[0027] With the aim of studying the enhancing effect of HBcAg at different doses in the murine model, 6 groups of 6 female BALB/c mice were selected. The schedule had three inoculations (days 0, 14 and 28) and two extractions (days 26 and 42). The assayed groups corresponded with: (1) HBsAg 5 μ g in PBS; (2, 3 y 4) HBsAg 5 μ g with 5, 10 y 20 μ g of HBcAg respectively, (5) HBsAg 5 μ g in acemannan 3mg/mL (dry weight) and (6) HBsAg 5 μ g in alum 0.5mg/mL. All groups except 6 were inoculated nasally. Group 6 was inoculated intramuscularly.

[0028] The Student's t test was used to analyse statistically the results, $p < 0.05$ was considered a significant difference.

[0029] In this experiment we concluded again that it is possible to enhance the anti-HBsAg response with the coinoculation of HBsAg and HBcAg. The serum IgG response for the three immunized groups with both antigens was significantly higher to that obtained by inoculation of HBsAg in PBS and similar to that attained by the group inoculated in acemannan. We have demonstrated previously that acemannan increased the titers to levels similar to that obtained by cholera toxin in mice. Titers obtained by systemic inoculation in alum did not differ from that of acemannan and

[0030] HBcAg/HBsAg groups by the nasal route. Although group 4 anti-HBsAg antibody response decreased as compared to group 3, the difference was due to a double increase in the HBcAg dose in-group 4. This increase might reduce the possibilities of HBsAg to penetrate mucosa.

Example 4

[0031] Different antigens were employed with the aim of studying the interaction of virus-like particles of Human Papilloma Virus 16 (VLP del VPH 16), HBsAg and HBcAg. Were immunized 8 groups of 6 female BALB/c mice with a schedule based in inoculations on days 0, 14 and the extraction 7 days after second inoculation.

[0032] Comparing antibody titers against HBsAg, the response of acemannan formulation (group 6) has the same intensity to the HBcAg/HBsAg formulation (group 7) respectively. This is the third time that we demonstrate the enhancing effect of HBcAg.

[0033] From this experiment we also concluded that neither acemannan nor HBcAg enhanced antibody responses against VLP of Human Papilloma Virus (HPV), represented as groups 4, 5 and 8 in the third graphic. Statistical analysis using Student's t test ($p < 0.05$ was considered a significant difference) did not show any difference between these groups.

[0034] Analysing the response against HBcAg in the group 5, where HBcAg and VLP of HPV were inoculated, low levels of antibody titers against HBcAg could be demonstrated as compared to group 7, where HBcAg was introduced along with HBsAg. Perhaps, the presence of these two particles antagonizes at the mucosal level. However, in group 2, high anti HBcAg and anti VLP of HPV could be achieved with the addition of HBsAg, being significantly higher the increase in these responses as compared to group 5 and do not differ from anti HBcAg response of group 7 (along with HBsAg). Hence we could realize a positive interaction between HBsAg and core antigens and a negative interaction between VLPs and HBcAg. The enhancing effect at mucosal level can occur in both senses, enabling the design of combined vaccines having as a nucleus HBsAg or the HBsAg/HBcAg combination.

[0035] HBsAg effect on group 2 not only enhanced the response against HBcAg, but it also enhanced the antibody response against the VLP of HPV. The same effect can be appreciated comparing the response against VLP between groups 1, 2 and 3 with group 8 where VLP were inoculated in PBS. Groups 1, 2 and 3 had statistically similar antibody levels, all of them higher than the group 8 level.

[0036] Group 1 (acemannan + HBsAg + VLPs HPV) and group 3 (HBsAg and VLP), did not differ in anti-HBsAg antibody titers. There was no statistical difference between group 3 and groups 6 and 7 (HBsAg/Acemannan and HBsAg/HBcAg respectively). This result evidenced the enhancing effect of VLP of HPV on HBsAg immunogenicity.

[0037] These results support the use of combined formulations through nasal routes with HBsAg as a central immunoenhancing antigen. For example, the simple mixture of HBsAg and HPV VLP is very attractive and makes real the possibility of introducing more antigens, enhanced by the interaction with HBsAg.

[0038] The creation of complex formulations is possible without reduction of antibody response against each component, for example: VLP of HPV, HBcAg and HBsAg can be mixed without affecting IgG response against each component.

Example 5

[0039] With the aim of demonstrating the immuno-enhancing activity of Hepatitis C Virus Nucleocapsid (HCV NC) on HBsAg when both are mixed and inoculated through the nasal route, 3 groups of 8 female BALB/c mice were assayed. A two inoculations schedule was carried out. The inoculations were on days 0, 14 and 28. The extraction was on day 42. The Group 1 was inoculated with 10µg of HCV NC, group 2 was inoculated with 5µg of HBsAg in PBS and group 3 with 5µg of HBsAg and 10µg of HCV NC in PBS (CIGB, La Habana) (Fig. 5).

[0040] The Student t test was performed to analyse statistically the results, $p < 0.05$ was considered a significant difference.

[0041] From this experiment we concluded that it is possible to enhance the IgG response with the mucosal (IN) coadministration of HBsAg and HCV NC. The IgG serum response was significantly higher compared to the group immunized with HBsAg in PBS.

DESCRIPTION OF FIGURES

[0042] **Figure 1.** Three doses schedule (days 0, 14 and 28). Extraction was performed on day 42. Groups 1 and 2 were inoculated with 50µL through the nasal route. Group 3 was inoculated subcutaneously with 100µL.

[0043] **Figure 2.** Two doses schedule (days 0 and 14). Extraction was performed on day 21. Groups 1, 2 and 3 were inoculated with 50µL through the nasal route. Group 4 was inoculated subcutaneously with 100µL.

[0044] **Figure 3.** Three doses schedule (days 0, 14 and 28). Extraction was performed on day 26. Groups 1, 2, 3, 4 y 5 were inoculated through the nasal route. Group 6 was inoculated intramuscularly with 100µL.

[0045] **Figure 4.** Two doses schedule (days 0 and 14). Extraction was performed on day 26. All groups were inoculated nasally with 50µL. The composition of experimental groups is shown in table added to the figure.

[0046] **Figure 5.** Two doses schedule (days 0, 14 and 28). Extraction was performed on day 42. Groups 1, 2 and 3 were inoculated with 50µL through the nasal route.

concentrations is in the range up to 1 mg each, preservatives and stabilizers can be added.

2. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is an antigen of viral nucleocapsid.
3. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigen of Hepatitis B Virus.
4. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Human Papilloma-Virus.
5. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Hepatitis C Virus.
6. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is a vaccine antigen of any nature or a mixture of different antigens receiving an immuno-enhancing effect from Hepatitis B surface antigen.
7. A vaccine formulation according to claims 1-6, administered as a solid, liquid or spray product.
8. A vaccine formulation according to claims 1-6 for mucosal administration.
9. A vaccine formulation according to claims 1-6 for use as a therapeutic vaccine.
10. A vaccine formulation according to claims 1-6 for use as a preventive vaccine.

Claims

1. A vaccine formulation for nasal administration wherein the components are (a) a surface antigen from virus and (b) one or more vaccine antigens synergizing in adjuvant effect with (a), the antigen

First schedule

1-10 μ g HBcAg / acemannan 3mg/mL

IN

2-10 μ g HBcAg / PBS 1X

IN

3-10 μ g HBcAg / alum 0.5mg/mL

SC




Fig. 1

Second Schedule

1-10 μ g HBsAg/ PBS 1X	IN
2-10 μ g HBsAg/ acemannan 3mg/mL	IN
3-10 μ g HBsAg/ 10 μ g HBcAg / PBS 1X	IN
4-10 μ g HBsAg/ Alum 0.5mg/mL	SC





Fig. 2

Third schedule

- | | |
|---------------------------------------|----|
| 1- 5 μ g HBsAg / PBS 1X | IN |
| 2- 5 μ g HBsAg / 5 μ g HBcAg | IN |
| 3- 5 μ g HBsAg / 10 μ g HBcAg | IN |
| 4- 5 μ g HBsAg / 20 μ g HBcAg | IN |
| 5- 5 μ g HBsAg / acemannan 3mg/mL | IN |
| 6- 5 μ g HBsAg / alum 0.5mg/mL | IM |

**Fig. 3**

Fourth Schedule: Synergism at mucosal level.

Acemannan 3mg/mL	X			X		X		
HBcAg 5 μ g/dose		X			X		X	
HBsAg 5 μ g/dose	X	X	X			X	X	
VLP /HPV 5 μ g/dose	X	X	X	X	X			X






Fig. 4 Composition, per groups, in the upper part of the figure.

Fifth Schedule

1-10 μ g HCV NC/ PBS 1X

IN

2-5 μ g HBsAg/ PBS 1X

IN

3-10 μ g HBsAg/ 10 μ g HCV NC / PBS 1X

IN




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/ CU 99 / 00006

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7 : A61K 39/29, 39/295		
According to International Patent Classification (IPC) or to both national classification and IPC B		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 : A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
CIBEPAT, EPOQUE, WPI, MEDLINE		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9412617 A1 (INTERNATIONAL BIOTECHNOLOGY LABORATORIES, INC.) 9 June 1994 (09.06.94), page 20, line 10-page 23, line 15 ; page 49, lines 6-34	1-3, 5-10
X	EP 0271302 A2 (SCRIPPS CLINIC AND RESEARCH FOUNDATION) 15 June 1988 (15.06.88), page 3, lines 10-30 ; page 7, line 47-page 8, line 50	1-3, 6, 9, 10
X	EP 0835663 A2 (SMITHKLINE BEECHAM BIOLOGICALS S.A) 15 April 1988 (15.04.88), page 3, line 12-page 4, line 50	1, 9, 10
X	US 5840303 A (CHISARI et al) 24 November 1998 (24.11.98), column 2, line 50-column 3, line 67	I
X	EP 0534615 A2 (CYTEL CORPORATION) 31 March 1993 (31.03.93), page 3, Line 5-page 5, line 32	I
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 23 February 2000 (23.02.00)		Date of mailing of the international search report 25 April 2000 (24.04.00)
Name and mailing address of the ISA		Authorized officer
		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 International Application No
PCT/CU 99/00006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5840303 A	24.11.1998	US 5932224 A US 5780036 A AU 679901 B ZA 9206440 A WO 9303753 A OA 9889 A NZ 270625 A NZ 244102 A HU 67529 A EP 0534618 A CZ 9400428 A CA 2115927 A BG 98522 A AU 2540892 A NO 940661 A FI 940919 A JP 6510050T T	03.08.1999 14.07.1998 17.07.1997 07.06.1993 04.03.1993 15.09.1994 20.12.1996 20.12.1996 28.04.1995 31.03.1993 15.02.1995 04.03.1993 31.05.1995 16.03.1993 19.04.1994 25.04.1994 10.11.1994
EP 0534615 A	31.03.1993	AU 687725 B NZ 270605 A NZ 244103 A ZA 9206441 A WO 9303764 A OA 9888 A HU 68510 A CZ 9400427 A CA 2115839 A BG 98523 A AU 2548792 A NO 940660 A FI 940918 A JP 6510051T T	05.03.1998 27.07.1997 27.07.1997 07.06.1993 04.03.1993 15.09.1994 28.06.1995 16.11.1994 04.03.1993 31.05.1995 16.03.1993 22.04.1994 08.04.1994 10.11.1994

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CU 99/00006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9412617-A	09.06.1994	AU 5679394 A	22.06.1994
EP 0271302 A	15.06.1988	PT 86318 A	01.01.1988
		DK 643387 A	10.06.1988
		US 5143726 A	01.09.1992
		US 4882145 A	12.11.1989
		US 4818527 A	04.04.1989
		CA 1329766 A	24.05.1994
		AU 8223187 A	09.06.1988
		AU 618942 B	16.01.1992
		JP 1025800 A	27.01.1989
EP 0835663 A	15.04.1988	US 6013264 A	11.01.2000
		AU 709406 B	26.08.1999
		IL 105770 A	16.08.1998
		DE 69319728T T	04.02.1999
		ES 2118963T T	01.10.1998
		CZ 283910 B	15.07.1998
		SG 48365 A	17.04.1998
		DE 69319728D D	20.08.1998
		AT 168271T T	15.08.1998
		PL 174077 B	03.06.1998
		EP 0835663 A	15.04.1998
		MX 9302982 A	01.12.1993
		AU 1648097 A	29.05.1997
		AP 567 A	25.11.1996
		ZA 9303541 A	21.06.1994
		WO 9324148 A	09.12.1993
		SK 142194 A	09.08.1995
		SI 9300271 A	31.12.1993
		NZ 253065 A	28.10.1996
		HU 71791 A	28.02.1996
		EP 0642355 A	15.03.1995
		CZ 9402892 A	13.09.1995
		CA 2136429 A	09.12.1993
		AU 4315693 A	30.12.1993
		NO 9444475 A	18.01.1995
		FI 945483 A	20.01.1995
		CN 1085450 A	20.04.1994
		JP 7308267T T	14.09.1995

Form PCT/ISA/210 (patent family annex) (July 1992)